Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PsyRx CNS Bio-TechXTAE:PSRX 12 3-Year RORE % is 0.00 as of . 20. GuruFocus rates XTAE:PSRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 948 Drug Manufacturers companies, PsyRx CNS Bio-Tech ranks worse than 105485.13% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
PsyRx CNS Bio-Tech does not have enough data to calculate 3-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
PsyRx CNS Bio-Tech 3-Year RORE % Related Terms
PsyRx CNS Bio-Tech 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for PsyRx CNS Bio-Tech's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PsyRx CNS Bio-Tech 3-Year RORE % Chart
PsyRx CNS Bio-Tech Annual Data
Trend
3-Year RORE %
PsyRx CNS Bio-Tech Semi-Annual Data
3-Year RORE %
XTAE:PSRX vs ZTS, UTHR, VTRS: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PsyRx CNS Bio-Tech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PsyRx CNS Bio-Tech 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PsyRx CNS Bio-Tech's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where PsyRx CNS Bio-Tech's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in . 20 and 3-year before.
PsyRx CNS Bio-Tech (XTAE:PSRX) has a 3-Year RORE % of 0.00 as of . 20. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PsyRx CNS Bio-Tech and its competitors. According to the industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 948 companies in the Drug Manufacturers industry.
Is PsyRx CNS Bio-Tech's 3-Year RORE % too high?
PsyRx CNS Bio-Tech's current 3-Year RORE % is 0.00. Based on the distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 948 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PsyRx CNS Bio-Tech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does PsyRx CNS Bio-Tech's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PsyRx CNS Bio-Tech ranks #999999 out of 948 companies for 3-Year RORE %. This places PsyRx CNS Bio-Tech in the lower half of its industry. The industry median 3-Year RORE % is 2.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.78, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PsyRx CNS Bio-Tech and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PsyRx CNS Bio-Tech's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyRx CNS Bio-Tech stock overvalued right now?
PsyRx CNS Bio-Tech (XTAE:PSRX) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. PsyRx CNS Bio-Tech's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For PsyRx CNS Bio-Tech (XTAE:PSRX), the current 3-Year RORE % is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PsyRx CNS Bio-Tech Ltd Formerly Cannabotech Ltd is engaged in the research and development of cannabis-based drugs. It is a biomedical company focused on the benefits of cannabinoids and medicinal mushrooms, applying the pure power of nature and science to health issues.
12GF Score
Get the complete analysis for XTAE:PSRX
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:PSRX has been successfully added to your 
